Aller au contenu principal
Accès ouvert déclaré 2024 article

Multiomics analysis to explore blood metabolite biomarkers in an Alzheimer’s Disease Neuroimaging Initiative cohort

33Citations signalées — pas une note de qualité
88Institutions déclarées
4Pays d’affiliation déclarés

Résumé fourni par la source

Abstract Alzheimer's disease (AD) is a neurodegenerative disease that commonly causes dementia. Identifying biomarkers for the early detection of AD is an emerging need, as brain dysfunction begins two decades before the onset of clinical symptoms. To this end, we reanalyzed untargeted metabolomic mass spectrometry data from 905 patients enrolled in the AD Neuroimaging Initiative (ADNI) cohort using MS-DIAL, with 1,304,633 spectra of 39,108 unique biomolecules. Metabolic profiles of 93 hydrophilic metabolites were determined. Additionally, we integrated targeted lipidomic data (4873 samples from 1524 patients) to explore candidate biomarkers for predicting progressive mild cognitive impairment (pMCI) in patients diagnosed with AD within two years using the baseline metabolome. Patients with lower ergothioneine levels had a 12% higher rate of AD progression with the significance of P = 0.012 (Wald test). Furthermore, an increase in ganglioside (GM3) and decrease in plasmalogen lipids, many of which are associated with apolipoprotein E polymorphism, were confirmed in AD patients, and the higher levels of lysophosphatidylcholine (18:1) and GM3 d18:1/20:0 showed 19% and 17% higher rates of AD progression, respectively (Wald test: P = 3.9 × 10 –8 and 4.3 × 10 –7 ). Palmitoleamide, oleamide, diacylglycerols, and ether lipids were also identified as significantly altered metabolites at baseline in patients with pMCI. The integrated analysis of metabolites and genomics data showed that combining information on metabolites and genotypes enhances the predictive performance of AD progression, suggesting that metabolomics is essential to complement genomic data. In conclusion, the reanalysis of multiomics data provides new insights to detect early development of AD pathology and to partially understand metabolic changes in age-related onset of AD.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Multiomics analysis to explore blood metabolite biomarkers in an Alzheimer’s Disease Neuroimaging Initiative cohort
Date Crossref
02/04/2024
Éditeur
Springer Science and Business Media LLC
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude et ne compte pas comme une seconde source scientifique indépendante.

Institutions déclarées

Tokyo University of Agriculture and TechnologyEisai (Japan)University of TsukubaYokohama City University Medical CenterRIKEN Center for Sustainable Resource ScienceRIKEN Center for Integrative Medical SciencesYokohama City UniversityUniversity of California, San FranciscoThe University of Texas Southwestern Medical CenterUC San Diego Health SystemMayo Clinic in FloridaBerkeley CollegeUniversity of California, BerkeleyUniversity of PennsylvaniaLAC+USC Medical CenterUniversity of California, DavisBrigham and Women's HospitalHarvard UniversityIndiana University BloomingtonWashington University in St. LouisPhiladelphia UniversityJanssen (United States)University of WashingtonSeattle UniversityUniversity of LondonUniversity of MichiganUniversity of UtahAlzheimer's AssociationBanner Alzheimer’s InstituteUniversity of PittsburghUniversity of California, IrvineUC Irvine HealthGeneral Electric (United States)Brown UniversityNational Institutes of HealthNational Institute on AgingOregon Health & Science UniversityUniversity of Southern CaliforniaUniversity of California San DiegoGeorgetown UniversityGeorgetown University Medical CenterBaylor College of MedicineColumbia University Irving Medical CenterUniversity of Alabama at BirminghamIcahn School of Medicine at Mount SinaiRush University Medical CenterJohns Hopkins UniversityNew York UniversityDuke Medical CenterUniversity of KentuckyUniversity of Rochester MedicineEmory UniversityUniversity of Kansas Medical CenterUniversity of California, Los AngelesJacksonville CollegeWinnMedYale UniversityJewish General HospitalMcGill UniversitySunnybrook Health Science CentreSt Joseph's Health CareCleveland ClinicLou Ruvo Brain InstituteNorthwestern UniversityPalm Beach NeurologyPremiere Research InstituteStanford UniversityBanner Sun Health Research InstituteHoward UniversityCase Western Reserve UniversityParkwood InstituteUniversity of Wisconsin–MadisonDent Neurologic InstituteThe Ohio State UniversityAlbany Medical Center HospitalHartford HospitalHartford Financial Services (United States)Dartmouth–Hitchcock Medical CenterWake Forest UniversityProvidence CollegeRhode Island HospitalButler HospitalMedical University of South CarolinaNathan Kline Institute for Psychiatric ResearchUniversity of IowaCornell UniversityUniversity of South FloridaUSF Health Byrd Alzheimer's Institute

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Sujets associés

Metabolomics and Mass Spectrometry StudiesAlzheimer's disease research and treatmentsTryptophan and brain disorders

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.